A Reversal for Gemphire Therapeutics Inc (NASDAQ:GEMP) Is Near. The Stock Has Decrease in Shorts

May 27, 2018 - By Linda Rogers

The stock of Gemphire Therapeutics Inc (NASDAQ:GEMP) registered a decrease of 4.11% in short interest. GEMP’s total short interest was 461,700 shares in May as published by FINRA. Its down 4.11% from 481,500 shares, reported previously. With 41,900 shares average volume, it will take short sellers 11 days to cover their GEMP’s short positions. The short interest to Gemphire Therapeutics Inc’s float is 10.81%.

The stock increased 4.44% or $0.27 during the last trading session, reaching $6.35. About 67,086 shares traded. Gemphire Therapeutics Inc. (NASDAQ:GEMP) has declined 45.18% since May 27, 2017 and is downtrending. It has underperformed by 56.73% the S&P500.

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver disease/non-alcoholic steatohepatitis . The company has market cap of $90.38 million. It is developing gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy and for those patients who present with NASH. It currently has negative earnings.

More important recent Gemphire Therapeutics Inc. (NASDAQ:GEMP) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on May 16, 2018, also Benzinga.com published article titled: “Benzinga’s Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down”, Benzinga.com published: “Benzinga’s Daily Biotech Pulse: Karyopharm’s STORM Study, Inogen Rallies On Earnings” on May 01, 2018. More interesting news about Gemphire Therapeutics Inc. (NASDAQ:GEMP) was released by: Nasdaq.com and their article: “Gemphire Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update” with publication date: May 08, 2018.

Gemphire Therapeutics Inc. (NASDAQ:GEMP) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: